NovoCure Limited

BMV:NVCR N Stock Report

Market Cap: Mex$27.1b

NovoCure Management

Management criteria checks 2/4

NovoCure's CEO is Asaf Danziger, appointed in Jan 2002, has a tenure of 21.92 years. total yearly compensation is $2.28M, comprised of 36.4% salary and 63.6% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth MX$3.55M. The average tenure of the management team and the board of directors is 3.3 years and 6.1 years respectively.

Key information

Asaf Danziger

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage36.4%
CEO tenure21.9yrs
CEO ownership0.01%
Management average tenure3.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Asaf Danziger's remuneration changed compared to NovoCure's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$174m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$831k

-US$93m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$876k

-US$58m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

US$12m

Dec 31 2020US$9mUS$782k

US$20m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$12m

Mar 31 2020n/an/a

US$9m

Dec 31 2019US$7mUS$702k

-US$7m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$41m

Mar 31 2019n/an/a

-US$55m

Dec 31 2018US$5mUS$693k

-US$64m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$59m

Mar 31 2018n/an/a

-US$64m

Dec 31 2017US$4mUS$698k

-US$62m

Sep 30 2017n/an/a

-US$73m

Jun 30 2017n/an/a

-US$95m

Mar 31 2017n/an/a

-US$114m

Dec 31 2016US$2mUS$651k

-US$132m

Compensation vs Market: Asaf's total compensation ($USD2.28M) is above average for companies of similar size in the MX market ($USD840.07K).

Compensation vs Earnings: Asaf's compensation has increased whilst the company is unprofitable.

CEO

Asaf Danziger (57 yo)

21.9yrs

Tenure

US$2,278,951

Compensation

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leadership Team

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman19.9yrsUS$2.15m0.52%
MX$ 139.7m
Asaf Danziger
President21.9yrsUS$2.28m0.013%
MX$ 3.5m
Ashley Cordova
Chief Financial Officer3.3yrsUS$6.84m0.067%
MX$ 18.0m
Wilhelmus C. Groenhuysen
Chief Operating Officer3.3yrsUS$6.62m0.16%
MX$ 42.9m
Pritesh Shah
Chief Growth Officerno dataUS$6.32m0.082%
MX$ 22.1m
Frank Leonard
President of CNS Cancers U.S.3.3yrsUS$6.13m0.051%
MX$ 13.8m
Yoram Palti
Founder & CTO23.9yrsUS$282.51kno data
Moshe Giladi
Chief Science Officerless than a yearno data0.0066%
MX$ 1.8m
Ingrid Goldberg
VP of Investor Relationsno datano datano data
Barak Arye
General Counsel1.7yrsno data0.0049%
MX$ 1.3m
Michael Puri
Chief Human Resources Officerless than a yearno datano data
Uri Weinberg
Chief Innovation Officerless than a yearno data0.057%
MX$ 15.5m

3.3yrs

Average Tenure

54yo

Average Age

Experienced Management: NVCR N's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman19.9yrsUS$2.15m0.52%
MX$ 139.7m
Asaf Danziger
President11.9yrsUS$2.28m0.013%
MX$ 3.5m
Jeryl Hilleman
Independent Director5.4yrsUS$445.20k0.0024%
MX$ 642.1k
David Hung
Independent Director5.6yrsUS$425.09k0.0063%
MX$ 1.7m
Timothy Scannell
Independent Director2.8yrsUS$439.44k0.000070%
MX$ 19.0k
Kinyip Leung
Independent Director12.2yrsUS$432.70k0.070%
MX$ 19.1m
William Vernon
Lead Independent Director17.9yrsUS$481.54k0.15%
MX$ 41.1m
Martin Madden
Independent Director6.6yrsUS$446.26k0.015%
MX$ 4.0m
Kristin Stafford
Independent Directorless than a yearno datano data
Allyson Ocean
Independent Directorless than a yearno datano data

6.1yrs

Average Tenure

61yo

Average Age

Experienced Board: NVCR N's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/30 11:48
End of Day Share Price 2023/10/02 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovoCure Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI
Emily BodnarH.C. Wainwright & Co.